M2a myeloid leukemia treatment plan is related to age, generally <60 years old patients treatment plan includes induction therapy, consolidation therapy. 1. Induction therapy: the initial treatment of adult M2a myeloid leukemia is based on anthraquinones such as zorubicin and desmethoxyzorubicin combined with chemotherapeutic drugs such as cytarabine. 2. Consolidation therapy: according to the cytogenetic molecular biology risk stratification and the patient’s willingness to comprehensive consideration. (1) High-risk group: allogeneic hematopoietic stem cell transplantation is preferred. (2) Intermediate-risk group: hematopoietic stem cell transplantation and chemotherapeutic drugs such as cytarabine and methotrexate can be used. (3) Low-risk group: large amounts of cytarabine-based consolidation chemotherapy are preferred. Patients aged between 60 and 75 years can be treated with the standard 3+7 (three days of anthraquinones and seven days of cytarabine) regimen of induction therapy if they are in good general condition. Patients aged >75 years are more likely to be treated with supportive therapy or low-intensity medications such as azacitidine and decitabine. The specific treatment plan for M2a myeloid leukemia should be decided by the doctor according to the patient’s situation comprehensively. All of the above drugs should be used reasonably under the guidance of a doctor, avoid self-medication.